Latest Quote @ Tue May 5 12:14:04 ( min delayed)
Last Day's Data
MDRNA, Inc. operates as a biotechnology company developing RNA-based technologies, including therapeutics based on RNA interference (RNAi) and microRNA. The company's primary focus is on the delivery of siRNAs in the treatment of a range of human diseases, including inflammation, viral infections, cancer, and metabolic disorders. MDRNA is pursuing pre-clinical RNAi programs in influenza and rheumatoid arthritis, from which it would identify appropriate target candidates for partnering and clinical development. The company has been building patent estates in the RNAi field, with approximately 260 filed patents addressing 144 gene sequences, including disease-validated targets. It seeks to monetize its nasal drug delivery business through licensing, partnering, or acquisition of its Phase II intranasal programs. MDRNA, Inc. was formerly known as Nastech Pharmaceutical Company, Inc. and changed its name to MDRNA, Inc. in June 2008. The company was incorporated in 1983 and is headquartered in Bothell, Washington.